Alkermes Overview

  • Year Founded
  • 1987

Year Founded

  • Status
  • Public

  • Employees
  • 2,100

Employees

  • Stock Symbol
  • ALKS

Stock Symbol

  • Investments
  • 14

  • Share Price
  • $24.42
  • (As of Tuesday Closing)

Alkermes General Information

Description

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

Contact Information

Formerly Known As
Antler Science Two, Antler Science Two Ltd
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Drug Discovery
Stock Exchange
NAS
Corporate Office
  • Connaught House
  • 1 Burlington Road
  • Dublin D04 C5Y6
  • Ireland
+353 (01) 000 0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Alkermes Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$24.42 $25.01 $20.46 - $32.88 $4.13B 169M 1.77M $2.62

Alkermes Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 4,121,445 4,125,113 4,118,691 3,620,812
Revenue 1,726,182 1,663,405 1,111,795 1,173,751
EBITDA 568,990 488,624 52,145 175,190
Net Income 434,430 355,757 (158,267) (48,169)
Total Assets 2,123,896 2,136,223 1,963,978 2,024,484
Total Debt 370,107 372,185 379,435 416,206
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Alkermes Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Alkermes‘s full profile, request access.

Request a free trial

Alkermes Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop,
Pharmaceuticals
Dublin, Ireland
2,100 As of 2023
00.000
000000000 00 00.000

000000

ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercit
000000000000000
Tokyo, Japan
00000 As of 0000
00000000

0000 0

magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris
000000000000000
Monmouth Junction, NJ
000 As of 0000
000000000 -
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Alkermes Competitors (32)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Astellas Pharma Corporation Tokyo, Japan 00000 00000000
Tris Pharma Private Debt Financed Monmouth Junction, NJ 000 000000000 -
AbbVie Corporation North Chicago, IL 00000 000.00 000000000 000.00
Nektar Therapeutics Formerly VC-backed San Francisco, CA 000 00.000 000000000 00.000
Arcturus Therapeutics Formerly VC-backed San Diego, CA 000 000.00 000000000 000.00
You’re viewing 5 of 32 competitors. Get the full list »

Alkermes Patents

Alkermes Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240182536-A1 Interleukin 18 variants Pending 11-Nov-2022 000000000
AU-2022263543-A1 Pharmaceutical compositions comprising sorbitan esters Pending 03-Nov-2022 0000000000
CA-3219506-A1 Substituted fused bicyclic macrocyclic compounds and related methods of treatment Pending 26-May-2021 0000000000
AU-2022281345-A1 Substituted fused bicyclic macrocyclic compounds and related methods of treatment Pending 26-May-2021 0000000000
AU-2022280804-A1 Substituted carbamate macrocyclic compounds and related methods of treatment Pending 26-May-2021 A61P21/00
To view Alkermes’s complete patent history, request access »

Alkermes Executive Team (37)

Name Title Board Seat Contact Info
Richard Pops Chief Executive Officer, Board Member & Chairman
Blair Jackson Executive Vice President & Chief Operating Officer
Iain Brown Senior Vice President, Chief Financial Officer
James Frates Chief Financial Officer & Senior Vice President
Don Reed Director, Business Development & Corporate Development
You’re viewing 5 of 37 executive team members. Get the full list »

Alkermes Board Members (19)

Name Representing Role Since
Brian Mckeon Self Board Member 000 0000
Cato Laurencin Ph.D Alkermes Board Member 000 0000
Christopher Wright Ph.D Self Board Member 000 0000
David Anstice Self Board Member 000 0000
David Daglio Alkermes Board Member 000 0000
You’re viewing 5 of 19 board members. Get the full list »

Alkermes Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Alkermes Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Alkermes‘s full profile, request access.

Request a free trial

Alkermes Investments & Acquisitions (14)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Rodin Therapeutics 25-Nov-2019 0000000000 00000 Drug Discovery 00000 000
Civitas Therapeutics 25-Aug-2014 00000 0000 0000 Drug Delivery 000000 00
Synchronicity Pharma 26-Nov-2013 00000 0000 000.00 Drug Discovery 00000 000
Civitas Therapeutics 11-Sep-2013 00000 0000 0000 Drug Delivery 000000 00
Acceleron Pharma 23-Dec-2011 Later Stage VC 000.00 Drug Discovery 0000000 0
You’re viewing 5 of 14 investments and acquisitions. Get the full list »

Alkermes Subsidiaries (1)

Company Name Industry Location Founded
Medisorb Pharmaceuticals Perm, Russia 0000
To view Alkermes’s complete subsidiaries history, request access »

Alkermes ESG

Risk Overview

Risk Rating

Updated May, 31, 2024

22.85 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,191

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 921

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 405

Rank

00.00

Percentile

To view Alkermes’s complete esg history, request access »

Alkermes Exits (8)

Company Name Exit Date Exit Type Exit Size Status Buyers
Civitas Therapeutics 25-Aug-2014 00000 00000 00 0000 Completed
  • 12 buyers
Civitas Therapeutics 11-Sep-2013 00000 00000 00 0000 Completed
  • 6 buyers
Acceleron Pharma 23-Dec-2011 00000 00000 00 000.00 Completed
  • 15 buyers
Civitas Therapeutics 12-Jul-2011 00000 00000 00 0000 Completed
  • 4 buyers
Acceleron Pharma 15-Dec-2009 Later Stage VC 0000 Completed
You’re viewing 5 of 8 exits. Get the full list »

Alkermes FAQs

  • When was Alkermes founded?

    Alkermes was founded in 1987.

  • Who is the CEO of Alkermes?

    Richard Pops is the CEO of Alkermes.

  • Where is Alkermes headquartered?

    Alkermes is headquartered in Dublin, Ireland.

  • What is the size of Alkermes?

    Alkermes has 2,100 total employees.

  • What industry is Alkermes in?

    Alkermes’s primary industry is Pharmaceuticals.

  • Is Alkermes a private or public company?

    Alkermes is a Public company.

  • What is Alkermes’s stock symbol?

    The ticker symbol for Alkermes is ALKS.

  • What is the current stock price of Alkermes?

    As of 18-Jun-2024 the stock price of Alkermes is $24.42.

  • What is the current market cap of Alkermes?

    The current market capitalization of Alkermes is $4.13B.

  • What is Alkermes’s current revenue?

    The trailing twelve month revenue for Alkermes is $1.73B.

  • Who are Alkermes’s competitors?

    Astellas Pharma, Tris Pharma, AbbVie, Nektar Therapeutics, and Arcturus Therapeutics are some of the 32 competitors of Alkermes.

  • What is Alkermes’s annual earnings per share (EPS)?

    Alkermes’s EPS for 12 months was $2.62.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »